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Tackling MARCKS-PIP3 circuit attenuates fibroblast
activation and fibrosis progression
David C. Yang,*,†,‡ Ji-Min Li,‡ Jihao Xu,‡ Justin Oldham,*,† Sem H. Phan,§ Jerold A. Last,*,† Reen Wu,*,†
and Ching-Hsien Chen‡,1
*Division of Pulmonary and Critical Care Medicine and ‡Division of Nephrology, Department of Internal Medicine, and †Department of
Internal Medicine, Center for Comparative Respiratory Biology and Medicine, University of California–Davis, Davis, California, USA; and
§Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
ABSTRACT: Targeting activated fibroblasts, including myofibroblast differentiation, has emerged as a key thera-
peutic strategy in patientswith idiopathic pulmonary fibrosis (IPF). However, there is no available therapy capable
of selectively eradicating myofibroblasts or limiting their genesis. Through an integrative analysis of the regulator
genes that are responsible for theactivationof IPF fibroblasts,wenoticed thephosphatidylinositol 4,5-bisphosphate
(PIP2)-bindingprotein,myristoylated alanine-richC-kinase substrate (MARCKS), as a potential targetmolecule for
IPF.Herein,wehave employed a 25-mer novel peptide,MARCKSphosphorylation site domain sequence (MPS), to
determine if MARCKS inhibition reduces pulmonary fibrosis through the inactivation of PI3K/protein kinase B
(AKT) signaling in fibroblast cells. We first observed that higher levels of MARCKS phosphorylation and the
myofibroblastmarkera-smoothmuscle actin (a-SMA)werenotablyoverexpressed inall tested IPF lung tissuesand
fibroblast cells. Treatment with the MPS peptide suppressed levels of MARCKS phosphorylation in primary IPF
fibroblasts.Akinetic assay confirmedthat thispeptidebinds tophospholipids,particularlyPIP2,withadissociation
constant of 17.64 nM. As expected, a decrease of phosphatidylinositol (3,4,5)-trisphosphate pools and AKT activity
occurred inMPS-treated IPF fibroblast cells. MPS peptide was demonstrated to impair cell proliferation, invasion,
andmigration inmultiple IPF fibroblast cells in vitro as well as to reduce pulmonary fibrosis in bleomycin-treated
mice in vivo. Surprisingly, we found that MPS peptide decreases a-SMA expression and synergistically interacts
with nintedanib treatment in IPF fibroblasts. Our data suggest MARCKS as a druggable target in pulmonary
fibrosis and also provide a promising antifibrotic agent that may lead to effective IPF treatments.—Yang, D. C., Li,
J.-M., Xu, J., Oldham, J., Phan, S. H., Last, J. A., Wu, R., Chen, C.-H. Tackling MARCKS-PIP3 circuit attenuates
fibroblast activation and fibrosis progression. FASEB J. 33, 14354–14369 (2019). www.fasebj.org
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Idiopathic pulmonary fibrosis (IPF) is a progressive in-
terstitial lung disease with poor prognosis and a median
survival of 2–3 yr. Of great concern, there are no currently
available therapies to stop disease progression (1, 2).
Although there are 2 therapeuticdrugspresently in clinical
use—nintedanib and pirfenidone—adverse effects due to
treatment sometimes necessitated dose reduction and/
or treatment interruption (3–5). Pirfenidone is an anti-
inflammatory and antifibrotic drug widely used for IPF
that has been shown to affect TGF-b–mediated fibroblast
activity; unfortunately, its mechanism of action is poorly
defined. Treatment with pirfenidone often results in ad-
verse effects such as photosensitivity, gastrointestinal
problems, skin rashes, andmore, sometimes necessitating
dose reduction (6). Nintedanib, an intracellular multi-
kinase inhibitor, in particular shows antifibrotic and
anti-inflammatory effects via blocking several key re-
ceptor tyrosinekinases, includingplatelet-derivedgrowth
factor receptor (PDGFR), fibroblast growth factor receptor
(FGFR), andVEGF receptor (VEGFR) (7, 8). However, this
drug does not completely inhibit the TGF-b pathway, an
important determinant in IPF pathogenesis (9, 10). Fur-
thermore, adverse effects are common with nintedanib
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therapy and worsen with higher dosages, which result
in drug discontinuation (11–13). Steroid therapy with
corticosteroids, along with other inflammatory drugs,
had long been standard therapy for patients with IPF
worldwide. However, the lack of large randomized
controlled monotherapy trials, minor benefit of treat-
ment, and significant morbidity from long-term corti-
costeroid treatments have resulted in recommendations
against use since 2011 and 2015 (14, 15). Because of a
lack of efficacy, unclear mechanisms of action, and
unfavorable adverse effect profiles of current therapies,
there is an urgent need to seek new and improved
therapeutics for those diagnosed with IPF.
Fibroblasts, specifically myofibroblasts, have been
implicated to play amajor role in the progression of IPF
through formation of fibroblastic foci, excessive de-
position of extracellular matrix (ECM), alveolar archi-
tecture distortion, and collagen deposition (16, 17).
Under normal conditions, fibroblasts express little ECM
production and cell-to-cell actin contacts. However,
after initial injury, fibroblasts can differentiate into
myofibroblasts, a contractile and secretory phenotype
marked by expression of a–smooth muscle actin
(a-SMA), which is indicative of fibroblast activation
and plays a critical role in the development and pro-
gression of IPF (18, 19). This activated phenotype can
impair lung function through tissue contraction and
excessive deposition of ECM. Previous studies have
demonstrated that multiple signaling proteins, such as
TGF-b, PI3K, and protein kinase B (AKT), are involved
in influencing fibroblast activation, myofibroblast dif-
ferentiation, and survival contributing to disease pro-
gression (9, 10, 20–22). Specifically, the transcription
factor AKT has been identified as a major convergence
factor of PDGFR and TGF-b signaling in IPF progression.
Upon activation, TGF-b is a potent growth factor and can
induce both the PDGFR and PI3K/AKT pathways, sub-
sequently promoting fibroblast recruitment, myofibro-
blast survival, and proliferation (22, 23). These long-lived
myofibroblasts play a major role in fibrosis, but the de-
tailed molecular mechanisms underlying fibroprolifer-
ative disorders is still incompletely understood.
Through an integrative analysis of the regulator genes
that are responsible for the activation of IPF fibroblasts,we
noticed the dysregulation of myristoylated alanine-rich
C-kinase substrate (MARCKS), a major PKC substrate.
MARCKS, a phospholipid binding protein, is a key regu-
latory protein controlling cell migration, exocytosis, and
phagocytosis (24–26). Recent studies have indicated that
an important function of the MARCKS phosphorylation
site domain (PSD), upon phosphorylation, is to provide
PI3K with phosphatidylinositol 4,5-bisphosphate (PIP2)
pools for phosphatidylinositol (3–5)-trisphosphate (PIP3)
production, thereby activating AKT (27–29). Based on the
sequence of theMARCKS PSD,we previously identified a
25-mer peptide, the MPS peptide, which targets the
MARCKS PSD sequence (MPS) and inhibits AKT activa-
tion in cancers (28, 30).
In this study, we show that phosphorylated MARCKS
is up-regulated in IPF tissues and in a mouse pulmonary
fibrosis model. In addressing the lack of an effective
treatment for IPF, we have not only identified the 25-mer
peptideMPS as a novel fibrotic agent but also provided an
alternative therapeutic strategy of improving the efficacy
of the multikinase inhibitor nintedanib for IPF treatment.
MATERIALS AND METHODS
Materials
DMEM, Roswell Park Memorial Institute (RPMI)1640 medium,
fetal bovine serum, and penicillin-streptomycin were purchased
from Thermo Fisher Scientific (Waltham, MA, USA). Lipofect-
amine and anti-PIP3 antibodywere also purchased from Thermo
Fisher Scientific). Vectastain Elite ABC Kit (rabbit IgG), Vector
HematoxylinQSnuclearcounterstain, and3,39-diaminobenzidine
(DAB) solution were purchased from Vector Laboratories (Bur-
lingame, CA, USA). Anti-phosphorylated (p)Ser158 MARCKS
(clone EP2113Y) and anti-MARCKS (clone EP1446Y) were pur-
chased from Abcam (Cambridge, MA, USA). Anti-pSer159/163
MARCKS (clone D13D2), anti-pSer473 AKT, anti-pSer308 AKT,
anti-AKT, anti–a-SMA, anti–glyceraldehyde 3-phosphate de-
hydrogenase, and anti–b-actin antibodies were purchased from
Cell Signaling Technology (Danvers, MA,USA). Hydroxyproline
assay kits were purchased from MilliporeSigma (Burlington,
MA, USA).
Plasmid constructs and primers
For generation of MARCKS short hairpin RNA (shRNA)
plasmids, the oligonucleotide of shRNAs (shRNA: 59-
GAGCGCTTCTCCTTCAAGAA-39 and its complementary strand:
59-TTCTTGAAGGAGAAGCGCTC-39)were synthesized, annealed,
and cloned into the pGreenPuro shRNA expression lentivector
(System Biosciences, Palo Alto, CA, USA). All primers for real-time
quantitative PCR used were as follows: the a-SMA forward, 59-
TCCTCATCCTCCCTTGAGAA-39 and the reverse, 59-ATGAAG-
GATGGCTGGAACAG-39; the collagen, type I, a-I chain (COL1A1)
forward, 59-ACGAAGACATCCCACCAATCACCT-39 and the re-
verse, 59-AGATCACGTCATCGCACAACACCT-39; the Thy-1 cell
surface antigen (THY1) forward, 59-AGAGACTTGGATGAGGAG-
39 and the reverse, 59-CTGAGAATGCTGGAGATG-39; the fibro-
nectin 1 (FN1) forward, 59-TCCACAAGCGTCATGAAGAG-39 and
the reverse, 59-CTCTGAATCCTGGCATTGGT-39; the vimentin
(VIM) forward, 59-AACTTCTCAGCATCACGATGAC-39 and the
reverse, 59-TTGTAGGAGTGTCGGTTGTTAAG-39; the MARCKS
forward, 59-TTGTTGAAGAAGCCAGCATGGGTG-39 and the re-
verse, 59-TTACCTTCACGTGGCCATTCTCCT-39.
Cell culture
Human primary fibroblast cells were obtained from airway tis-
sues provided from the University of California (UC) Davis
Medical Hospital (Sacramento, CA, USA) with consent. The
protocol for human tissue procurement and usage was periodi-
cally reviewed and approved by the University Human Subject
Research Review Committee. Primary fibroblast cell lines, IPF-1,
-2, -3, and -4 cells, were established from patients with IPF. Cells
were obtained from lung biopsies, and the diagnosis of IPF was
supported by patient history, physical examination, pulmonary
function tests, and typical high-resolution chest computed to-
mography findings of IPF. In all cases, the diagnosis of IPF was
confirmed by microscopic analysis of lung tissue and demon-
strated the characteristic morphologic findings of usual in-
terstitial pneumonia. All patients fulfilled the criteria for the
diagnosis of IPF as established by the American Thoracic Society
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and European Respiratory Society. Nonfibrotic primary control
adult human lung fibroblast lines Normal-1, -2, and -3 cells were
used. These lines were established from normal lung tissue or
histologicallynormal lungtissueadjacent to carcinoid tumor.The
IPF cell line, LL97A, was purchased from the American Type
Culture Collection (Manassas, VA, USA). Lung fibroblast lines
were cultured in high-glucoseDMEMorRoswell ParkMemorial
Institute-1640 medium with 10% fetal bovine serum and 1%
penicillin-streptomycin at 37°C in a humidified atmosphere of
5% CO2. Fibroblasts were used less than passages 8. Cells were
characterized as fibroblasts as previously described (31).
Real-time quantitative PCR
The mRNA expression level of target genes was detected by
real-time RT-PCR using primers as described in the Supple-
mental Data. The housekeeping gene TATA-box bindingprotein
(TBP) was used as the reference gene. The relative expression
level of target genes compared with that of TBP was defined as
–DCt = –[Ct target–Ct TBP]. The target/TBP mRNA ratio was cal-
culated as 2–DCt3 K, where K is a constant.
Patient lung specimens and
immunohistochemical staining
IPF lung tissue and non-IPF normal lung specimens were
obtained from patients with histologically confirmed IPF who
underwent surgical resection at the UC Davis Medical Center.
This investigation was approved by the Institutional Review
Board of theUCDavisHealth System.Written informed consent
was obtained from all patients. All patient samples were
de-identified and provided by the UC Davis Interstitial Lung
Disease Program. Formalin-fixed and paraffin-embedded speci-
mens were used, and level of phospho-MARCKS was analyzed
by immunohistochemical (IHC) staining as previously described
(28). Detailed experimental procedures were modified from the
paraffin immunohistochemistry protocol supplied by the man-
ufacturer (Cell Signaling Technology). The slides were depar-
affinized in xylene substitute and rehydrated in graded alcohol
and water. An antigen retrieval step [10 nM sodium citrate (pH
6.0) at a subboiling temperature] was used for each primary an-
tibody. Endogenous peroxidase activity was blocked by 3% hy-
drogen peroxide followed by blocking serum and incubation
with appropriate antibodies overnight at 4°C. Detection of
immunostaining was carried out by using the Vectastain ABC
system, according to the manufacturer’s instructions (Vector
Laboratories). A 4-point staining intensity scoring system was
devised to confirm the relative expression of phospho-MARCKS
in lung specimens; scores ranged from 0 (no expression) to 3
(highest-intensity staining) as previously described (28, 32–34).
The resultswere classified into2groupsaccording to the intensity
and extent of staining: in the low-expression group, stainingwas
observed in 0–1% of the cells (staining intensity score = 0), in
,10%of the cells (staining intensity score=1), or in 10–25%of the
cells (staining intensity score = 2); in the high-expression group,
stainingwaspresentmore than25%of thecells (staining intensity
score = 3).
Peptide synthesis
The MPS, control, and scrambled peptides (95% pure) were
purchased from EZBiolab (Carmel, IN, USA). The MPS peptide
consisted of 151–175 aa from thewild-type protein, KKKKKRFS-
FKKSFKLSGFSFKKNKK; the control peptide had a sequence
KKKKKRFDFKKDFKLDGFDFKKNKK, and the scrambled
peptide had a sequence KRFLSKKKNKSFFGKSKKFKKKKSF.
Peptides were reconstituted in PBS, yielding stock concentra-
tions of 10 mM. Stock solutions were stored at 220°C and di-
luted to desired concentrations on the day of the experiment.
Kinetic assay
Real-time bindingof the peptidemimicking the phosphorylation
site domain of MARCKS (MPS peptide, 151–175 aa from the
wild-type MARCKS protein) to biotin-labeled PIP2 was evalu-
ated using biolayer interferometry on an Octet RED96 system
(Forte´Bio, Fremont, CA, USA) following the manufacturer’s in-
structions. Briefly, the ligand, PIP2 labeledwith biotin at the sn-1
position [1000nMindoubledistilled (dd)H2O],was immobilized
onSuperStreptavidinbiosensors for10min.Abindingassaywas
performed with theMPS analyte at various concentrations from
0 to 1000 nM in ddH2O. Association and dissociation were
monitored for 5min. Assays were performed at 24°C. Data were
analyzed using Octet Data Analysis Software 7.0 (Forte´Bio).
PIP3 quantitation
Cells were harvested and precipitated by trichloroacetic acid.
PIP3 lipids were extracted twice from the trichloroacetic acid
precipitated fraction by methanol:chloroform (2:1). After acidi-
fication, organic-phase lipids were used for PIP3 quantitation,
based on the protocol for the PIP3 Mass ELISA Kit (Echelon
Biosciences, Salt Lake City, UT, USA). Briefly, the lipid extract
from cultured cells was mixed with the PIP3-specific detector
protein, which was then incubated in a PIP3-coated microplate
for competitive binding. After several washes, the microplate
was then incubated with an horseradish peroxidsase–linked
secondary detector and tetramethylbenzidine substrate for color
development. To stop further color development, 2 M H2SO4
solutionwas thenadded.Microplateswerereadat anabsorbance
wavelength of 450 nm. A series of different dilutions of PIP3
standards were used to establish a standard curve for each
reaction. Cellular PIP3 amounts could be estimated by compar-
ing the absorbance in the wells with the values in the standard
curve. Experiments were conducted in triplicate dishes and re-
peated in 2 independent cultures with cell density 53 106 cells/
100-mm dish.
Transwell invasion assay
An in vitro cell invasion assay was performed as previously de-
scribed (27, 28) using Transwell chambers (8-mm pore size; Co-
star;MilliporeSigma). Briefly, 23 104 cells were seeded on top of
the polycarbonate filters that were coated with Matrigel (Becton
Dickinson, Franklin Lakes, NJ, USA), and 0.5 ml of growth me-
dium with scrambled or MPS peptide (100 mM) was added to
both the upper and lower wells. After incubation for 20 h, filters
were swabbedwith a cotton swab, fixedwithmethanol, and then
stained with Giemsa solution (MilliporeSigma). The cells at-
tached to the lower surface of the filterwere countedunder a light
microscope (310 magnification).
Scratch wound healing assay
Cells were seeded to 6-well tissue culture dishes and grown to
confluence. A linear wound was introduced to each confluent
monolayer using a pipette tip and washed 3 times with PBS.
Thereafter, cell morphology and migration were observed and
photographed at regular intervals for 12 and 24 h. The number of
cells migrating into the cell-free zone was acquired under a light
microscope and counted.
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Immunoblotting and immunofluorescent staining
Western blot analyses and the preparations of whole-cell lysates
have been previously described (28, 30, 34). For whole-cell ly-
sates, cells were lysed in a lysis buffer [50 mMTris-HCl (pH 7.4),
1% Triton X-100, 10% glycerol, 150 mM NaCl, 1 mM EDTA, 20
mg/ml leupeptin, 1 mM PMSF, and 20 mg/ml aprotinin] and
separated by SDS-PAGE. Immunoblotting was conducted
using appropriate antibodies followed by chemiluminescent
detection. For immunofluorescent staining, after an antigen re-
trieval step, tissue slides were reacted with antibodies against
FITC-labeled antibody (anti-PIP3 or anti–a-SMA) and
tetramethylrhodamine-conjugated antibody (anti-MARCKSor
anti–phospho-MARCKS), and nuclei were demarcated with
DAPI staining. The cells were mounted onto slides and visu-
alized using fluorescence microscopy (model Axiovert 100;
Carl Zeiss GmbH, Oberkochen, Germany) or a Zeiss LSM510
laser-scanning confocal microscope image system.
Bleomycin-induced lung fibrosis
Female C57BL/6J mice (8-wk-old) purchased from The Jackson
Laboratory (Bar Harbor, ME, USA) were housed 4 mice/cage
and fed autoclaved food ad libitum. Thesemice received saline or
bleomycin intratracheally as previously described (35). Briefly,
mice were anesthetized with 5% isoflurane and administered
bleomycin (APP Pharmaceuticals, Schaumburg, IL, USA) at a
dose of 0.005 U/g mouse via intratracheal aspiration on d 0.
Control animals received an equal volume of sterile saline only.
In early fibrogenic phase, these mice were intraperitoneally in-
jected with either PBS, or MPS peptide (28 mg/kg) every 2 d. At
21 d of bleomycin insult, these mice were euthanized, and the
lungs were collected for histologic analysis. Mouse experiments
were approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of University of California–Davis (UCDavis). If
the event of any unexpected adverse effects arises, Campus
Veterinary Services will be contacted and UC Davis IACUC
policy on Humane Endpoints will be followed.
Hydroxyproline assays
Lung tissues collected from mouse experiments were cut into
smaller pieces and homogenized in 100 ml ddH2O/10 mg tissue
using a sonicator (VC50 Vibra-Cell; Sonics and Materials, New-
town, CT, USA). Hydrochloric acid 100 ml (12 M)/10 mg tissue
was added and samples were transferred into glass Wheaton
ampules (Wheaton,Millville,NJ,USA) and sealed. Sampleswere
hydrolyzed for 3 h at 120°C. Samples were allowed to cool,
transferred into microcentrifuge tubes, and then centrifuged at
10,000 g for 3 min. Supernatant was retrieved and 10–50 ml were
transferred to a clear 96-well flat-bottomed plate. The plate was
dried at 60°C and assay was prepared, read at 560 nm, and
hydroxyproline content was calculated according to the manu-
facturer’s instructions (MilliporeSigma).
Cell proliferation and colony formation assays
Cells were seeded onto 96-well plates at a density of 52103 103
cells/well and cultured for the indicated treatment. Cell pro-
liferation was evaluated using an MTS assay kit (Promega,
Madison, WI, USA). Twenty microliters of the combined MTS/
phenazine methosulfate solution was added into each well, in-
cubated for 3 h at 37°C, and the absorbancewasmeasured at 490
nm by using an ELISA reader. For Trypan blue test, cells
were plated on 12-well plates and treated with the indicated
chemotherapeutic agents.After 72 h, both attached anddetached
cellswerecollectedand then stainedwith0.2%Trypanblue (0.1%
final concentration), andthenumberofTrypanblue–positiveand
negative cells was counted using a hemocytometer under
low-power microscopy. For colony-forming assays, 200 cells
were seeded in each well of the 6-well plates. IPF-1 or IPF-2
primary cells were treated with peptides at the indicated con-
centrations for 10 d. Colonies were stained using 0.001% crystal
violet, and the number of colonieswith a diameter.0.5mmwas
counted under an inverted microscope.
Evaluation of therapeutic interactions
The therapeutic interactions between the multikinase inhibitor
nintedanib and MPS peptide were evaluated according to the
method of Chou and Talalay (36) with the help of the Calcusyn
software suite (Biosoft, Cambridge, United Kingdom). Combi-
nation index (CI) values were determined by generating
dose-response curves for various concentrations of nintedanib
(0.625–20 mM) treatment in conjunction with MPS peptide
(6.25–200 mM) and then calculated at different drug concentra-
tions. According to Chou and Talalay, a CI of ,1 indicates a
synergistic interaction, a CI of 1 indicates an additive interaction,
and a CI of.1 indicates an antagonistic interaction.
Statistical analysis
Data are presented as the means6 SD for at least 3 independent
experiments. The quantitative in vitro and in vivo data were an-
alyzed using the Student’s t test. The difference in patient char-
acteristics between the high-expression and low-expression
groups was analyzed using Fisher’s exact test. All analyses were
performed using SPSS software (v.10.0; SPSS, Chicago, IL, USA).
All statistical tests were 2-sided, and values of P , 0.05 were
considered statistically significant.
RESULTS
Aberrant elevation of MARCKS expression
and its relevance to IPF fibroblasts
To discover the regulators of IPF fibroblast activation, we
compared and integrated the gene profiles of IPF fibro-
blasts from 2 different microarray platforms. Among the
genes identified, MARCKS was found to be highly asso-
ciated with the expression of the myofibroblast marker
a-SMA and was notably overexpressed in IPF fibroblasts
(unpublished results). Through the analysis of the tran-
scriptomedataset (WangX.M., ZhangY., KimH. P., Zhou
Z., Feghali-Bostwick C. A., Liu F., Ifedigbo E, Xu X., Oury
T. D., Kaminski N., and Choi A. M.) (37), we compared
MARCKS gene expression between 15 samples obtained
fromsurgical remnants of biopsies or lungs explanted from
patients with IPF that underwent pulmonary transplant
and 11 normal histology lung samples resected from pa-
tients with lung cancer. Data analyzed with the Wilcoxon/
Mann-Whitney tests demonstrated that MARCKS
mRNA levels were significantly higher in IPF lung tis-
sues than in normal lung tissue sections (Fig. 1A,P, 0.05).
To validate that MARCKS is dysregulated in IPF fibro-
blasts, we examined MARCKS expression and its phos-
phorylation in primary lung fibroblast cells isolated from
patients with IPF and those with non-IPF. Figure 1B shows
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increased expression of MARCKS mRNA (left) and higher
levels of phospho-MARCKS,MARCKS, and a-SMA (right)
in 2 IPF fibroblast cells (IPF-1 -2) as compared with normal
fibroblasts (Normal-1 and -2), suggesting the implications of
high MARCKS expression in IPF fibroblasts.
Because MARCKS’s function depends on its phos-
phorylation at Ser159 and Ser163, we next histologically
confirmed phospho-MARCKS levels in both normal lung
samples and IPF lung tissues from patients. IHC analysis
of MARCKS phosphorylation showed an increase of
phospho-MARCKS signals in the tissue sections from
patients with IPF (Fig. 1C). We also found that higher
levels of MARCKS phosphorylation occurred in IPF
vs. normal tissues at 75 vs. 15%, respectively (Fig. 1D),
and there was a positive correlation between phospho-
MARCKS and IPF status (Fig. 1D, P = 0.041). Utilizing
immunofluorescence and confocal microscopy, we ob-
served detachment of MARCKS protein from the cell
membrane occurred in primary IPF fibroblast cells, sug-
gestingup-regulationofMARCKSphosphorylation in IPF
Figure 1. MARCKS is up-regulated in IPF. A) Normalized expression of MARCKS in IPF tissues (n = 15) vs. normal histology lung
tissue samples (n = 11) using the GSE2052 dataset. B) Left: expression of MARCKS mRNA in primary normal ﬁbroblasts (Normal-
1 and -2) and primary IPF ﬁbroblast cells (IPF-1 and IPF-2) as measured by real-time quantitative RT-PCR (n = 5). *P , 0.05 vs.
Normal-1. Right: MARCKS protein and its phosphorylation was determined by Western blotting. C, D) Higher IHC staining of
MARCKS protein in IPF tissues vs. normal lung tissue samples. C) Representative images utilizing anti-pSer159/163 MARCKS
mAb in normal lung tissue (n = 7) and IPF specimens (n = 8) from patients. P1, P2, and P3 are 3 representative patients. Scale
bar, 100 mm. D) Percentage of patients with high and low levels of phospho-MARCKS expression corresponding to normal and
IPF. Numbers in bars represent the percentage of patients for each condition. E) Expression levels of MARCKS and PIP3 in 3
primary normal ﬁbroblasts and IPF ﬁbroblast cells as stained with anti-MARCKS and anti-PIP3 antibodies. The ﬂuorescence of
tetramethylrhodamine –conjugated MARCKS (red) and FITC-conjugated PIP3 (green) as well as nucleus counter-stained DAPI
(blue) was visualized under a confocal laser-scanning microscope. Scale bar, 10 mm.
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fibroblasts (Fig. 1E). We next quantified the above immu-
nofluorescence signal intensity and we found that IPF fi-
broblasts expressed higher levels of PIP3 pools, as
compared with primary normal fibroblasts (Fig. 1E and
Supplemental Fig. S1A). Thus, phospho-MARCKS is
likely of high importance in patients with IPF.
MARCKS inhibition down-regulates PIP3
production, AKT activity, and
a-SMA expression
Given the importance of the PSD in the functionality of
MARCKS protein, we previously developed the 25-mer
MPS peptide to mimic the MARCKS PSD and showed
that this peptide can directly inhibit phospho-MARCKS–
mediated functions in cancers while having no cytotoxic
effect on normal human bronchial epithelial cells (28, 30).
Treatmentwith theMPSpeptide in primary IPF fibroblast
cells confirmed that this peptide had an inhibitory effect
on MARCKS phosphorylation (Fig. 2A), and this effect
appeared to be dose- and duration-dependent. On the
basis of the PIP2-bindingmotif on the MARCKS PSD, we
first tested the effect of this peptide on PIP2 binding and
PIP3 synthesis, which are the 2 major determinants for
AKT activation (29). A kinetic assay confirmed that this
peptide binds PIP2 with a dissociation constant of 17.64
nM (Fig. 2B). As expected, a decrease of PIP3 pools in
MPS-treated IPF fibroblasts was observed (Fig. 2C, D),
supporting the notion that MPS peptide is able to inhibit
AKT activation by trapping PIP2. Indeed, Western blot
analysesofphospho-AKTexpressionrevealedconcentration-
dependent decrease of phospho-AKT levels in cultures
treated with the MPS peptide but not in cultures treated
with the scrambled peptide (Fig. 3A).
To determine a causal effect of MARCKS inhibition on
hallmarks of activated fibroblasts, we examined mRNA
levels of COL1A1, FN1, THY1, VIM, and the most de-
finitive molecular marker of myofibroblasts, a-SMA after
treatmentwithMPSpeptide. TreatmentwithMPSpeptide
in IPF fibroblast cells resulted in decreased levels of CO-
L1A1 and fibronectin (Fig. 3B, C and Supplemental Fig.
S2A, B). Strikingly, MPS-treated IPF fibroblast cells dis-
played significantly lower mRNA (Fig. 3D) and protein
(Fig. 3E) expression of a-SMA as compared with cells re-
ceiving PBS or scrambled peptide. Because TGF-b is a
major profibrogenic factor for a-SMA induction, primary
normal lung fibroblasts were either treated with TGF-b
alone or cotreated with TGF-b and MPS peptide. After
48h,TGF-b treatmentpromotedexpressionofa-SMAand
phospho-AKT abundance,whereas TGF-b–induceda-SMA
expression was inhibited in the presence of MPS peptide
(Supplemental Fig. S2C). Altogether, these data suggest
an association of theMARCKS PSDwith AKT activation
and with myofibroblast differentiation.
MPS treatment suppresses IPF fibroblast
activation in vitro
Based on the abovemolecular findings, we next examined
whetherMPSpeptide inhibits the important determinants
of fibrosis progression including cell proliferation, in-
vasion, and migration. Two primary IPF fibroblast cells
(IPF-1 and IPF-2), 1 IPF fibroblast cell line (LL97A), and
primary normal fibroblast cells (Normal-1) were treated
with various doses of MPS peptide for 72 h. Remarkably,
impaired cell proliferation was noted in MPS-treated fi-
broblast cells with only a slight decrease of cell viability
observed in normal cells (Fig. 4A). In addition, data from
Trypan blue exclusion test indicated that cell viability was
significantly lower with 50 mM MPS treatment as com-
pared with PBS or scrambled peptide group (Fig. 4B). We
also observed a dose-dependent decrease of colony-
forming ability in cells exposed to MPS peptide (Fig. 4C).
Cell invasiveness in Matrigel-coated Transwells was also
suppressed in the primary IPF fibroblasts, IPF-1 and IPF-2
cells, after MPS peptide treatment, whereas no suppres-
sionwas seenwith scrambled peptide treatment (Fig. 4D).
Treatment of the primary IPF fibroblast cells with MPS at
100 mM reduced cell motility, as observed in wound-
healing assays at 12 and 24 h postwound (Fig. 4E). We
also used a MARCKS-shRNA to deplete endogenous
MARCKS to determine whether an increase in phospho-
MARCKS or total MARCKS abundance promotes cell
motility of lung fibroblasts. As shown in Supplemental
Fig. S3A, silencingMARCKSexpression inhighMARCKS-
expressing fibroblast cells resulted in reducing cell mi-
gration, as compared with control shRNA-transduced
cells.
The PI3K/AKT pathway participates in multiple com-
plex signaling cascades, but PI3K inhibitors have had
lackluster results thus far (38) when taken into clinical use.
To further confirm the cytotoxicity of PI3K inhibition, we
treated both types of cells with the PI3K inhibitor
LY2940002. Unlike the selective effect observed with MPS
on cells, the PI3K inhibitor exhibited a similar halfmaximal
inhibitory concentration between IPF and normal fibro-
blast cells: 1262 nM in IPF-1 cells, 1088 nM in IPF-2 cells,
and 745 nM in Normal-1 cells. These results demonstrate
that MPS peptide has a suppressive activity on cell pro-
liferation, invasion, andmigration in IPF fibroblasts but not
in normal fibroblast cells.
MPS peptide potentially serves as an
antifibrotic agent in a bleomycin-induced
pulmonary fibrosis
To translate our findings from in vitro into in vivo, we
carried out the bleomycin-induced pulmonary fibrosis
mouse model: 8-wk-old C57BL/6J mice received saline or
bleomycin intratracheally as previously described (35).
Lung specimens from C57BL/6J mice with either intra-
tracheal administration of bleomycin (33 mg in 50 ml of
saline) or saline were collected at d 21 after last bleomycin
application. The paraffin-embedded lung sections were
subjected to immunofluorescence staining by using anti–
phospho-MARCKS and anti–a-SMA antibodies (Fig. 5A).
Data from immunofluorescence staining demonstrate
elevated coexpression of phospho-MARCKS and
a-SMA in bleomycin-treated lung tissues compared
with those in the saline control (Fig. 5B), suggesting
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the potential role of phospho-MARCKS abundance in
myofibroblast cells and pulmonary fibrosis. Next, lung
fibroblast cells isolated from saline- or bleomycin-treated
mice were incubated with either PBS or 100 mM MPS
peptide for 72 h. Fibroblasts from bleomycin-treated
mice exhibited a decrease in phospho-MARCKS,
phospho-AKT, and a-SMA expression in the presence of
MPS (Fig. 5C). Moreover, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assays con-
firmed thatMPS treatment is very effective in decreasing
cell viability of these fibroblast cells, as compared with
the treatment of fibroblast cells from saline-treated mice
(Fig. 5D).
Furthermore, we tested the feasibility of the MPS pep-
tide as an antifibrotic agent in the bleomycin-induced
pulmonary fibrosis mouse model. Upon bleomycin ex-
posure for 9 d, the body weight of mice was obviously
decreased, as comparedwithmicereceiving saline (control
group). Saline- and bleomycin-exposed mice then were
treated with either PBS or MPS peptide intraperitoneally.
To ascertain the therapeutic effect of MPS peptide
on pulmonary fibrosis, MPS was administered in-
traperitoneally during the fibrotic phase of the model.
Figure 6A illustrates the protocol forMPS administered in
this study. In total, therewere 4 groups (5mice/group): 1)
salineplusPBS;2) saline plusMPS; 3) bleomycinplusPBS;
Figure 2. The mimetic of MARCKS, MPS peptide, targets phospho-MARCKS, binds to PIP2, and inhibits production of PIP3
pools. A) MPS peptide treatment inhibited MARCKS phosphorylation of primary IPF ﬁbroblast cells. Left: cells were exposed to
either 100 mM control peptide or 25–100 mM MPS peptide for 48 h and then subjected to Western blot analysis. Right: Western
blot analysis of phospho-MARCKS levels in IPF ﬁbroblasts after MPS treatment for 0, 12, 24, 48, and 72 h. B) Biolayer
interferometry analysis of the binding of the MPS peptide to biotin-labeled PIP2. C) PIP3 levels in primary IPF ﬁbroblast cells.
*P , 0.05 vs. control PBS (means 6 SD). D) Multiple primary IPF ﬁbroblasts were exposed to either PBS or 100 mM MPS peptide
for 12 h and subjected to immunocytochemistry using anti-PIP3 antibody. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Representative images are shown (n = 3). Scale bars, 20 mm.
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and 4) bleomycin plus MPS. Surprisingly, we found a
continued loss of body weight in the mice exposed to
bleomycin plus PBS but not in the bleomycin-exposed
micewithMPS treatment (Fig. 6B).After22dofbleomycin
exposure, mice lungs were collected and processed for
histology and collagen content analysis. Bleomycin-
exposed mice showed extensive structural changes in
the lungs, whereas decreases of both fibroblastic lesions
and deposited ECM were seen in the lungs from these
mice with bleomycin exposure and MPS treatment (Fig.
6C). In an attempt to compare the antifibrotic effects be-
tween MPS peptide and nintedanib, the currently FDA-
approved therapeutic agent for IPF, we conducted the
other cohort of bleomycin-induced pulmonary fibrosis
studies. These bleomycin-exposed mice were intraperitone-
ally injectedwithnintedanib (28mg/kg) orMPSpeptide (28
mg/kg) every 2 d for 7 injections (n = 6 mice/group). IHC
staining showed a concomitant decrease of phospho-
MARCKS and phospho-AKT levels in bleomycin-exposed
lung tissues receivingMPS (Fig. 6D). Down-regulated levels
of hydroxyproline were seen in the lungs from the bleomy-
cin plus MPS group (Fig. 6E). These results suggest a po-
tential therapeutic application of MPS peptide in the
treatment of pulmonary fibrosis.
Synergistic antitumor efficacy of a
multikinase inhibitor and MARCKS inhibition
The potent multikinase inhibitor nintedanib was docu-
mented to show antifibrotic and anti-inflammatory effects
(7, 8).However,weobservedan increaseofa-SMAprotein
upon nintedanib treatment (Fig. 7A) in IPF fibroblast cells,
which agrees with the recent report that nintedanib in-
duces a-SMA (39). We also confirmed a significant in-
crease in mRNA expression of a-SMA but a decrease of
FN1 mRNA levels in nintedanib-treated cells (Supple-
mental Fig. S4). Surprisingly, there was no change in
phospho-AKT levels after nintedanib treatment (Fig.
7B). On the contrary, treatment with MPS peptide
Figure 3. Targeting phospho-
MARCKS by MPS peptide sup-
presses AKT activation and
myoﬁbroblast-associated gene
expression. A) Primary IPF ﬁ-
broblasts, IPF-1 cells, were in-
cubated in a medium containing
200 mM scrambled or various
dosages of MPS peptide for 48 h
and harvested for Western blot-
ting. B–D) Myoﬁbroblast-associ-
ated gene expression, including
COL1A1 (B), FN1 (C), and
a-SMA (D) in MPS-treated IPF
ﬁbroblasts. Cells from near-con-
ﬂuent cultures were harvested
for RNA isolation, and the level
of expression was quantiﬁed
with real-time quantitative RT-
PCR and expressed as fold
change relative to PBS-treated
cells (n = 4). E) a-SMA protein
level was conﬁrmed by Western
blotting. GAPDH, glyceralde-
hyde 3-phosphate dehydroge-
nase. A representative example
of 3 independent experiments is
shown. *P , 0.05.
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Figure 4. MPS peptide treatment impairs cell proliferation, invasiveness, and migration of primary IPF ﬁbroblasts. A) Cells were
incubated with various concentrations of the MPS peptide for 72 h and then subjected to MTS proliferation assays. B) IPF-1 cells
were exposed to either 200 mM scrambled peptide or 25–200 mM MPS peptide. After 72 h, cell morphology (top) was
photographed and cell viability (bottom) was determined by Trypan blue exclusion assay (n = 6). Cell viability was calculated by
the number of viable cells/the number of total cells 3 100. C) Cells were treated with the indicated concentrations of MPS
peptide, and colonies were counted after 9 d using crystal violet staining. Top, data are representative of 3 independent
experiments. Bottom, colony units (n) (means 6 SD). D) Invasion ability of cells with or without MPS peptide as determined by
Matrigel invasion assays. Dissociated cells of IPF-1 and -2 cultures were plated on Transwells with PBS, scrambled, or MPS peptide
(100 mM), 20 h later, cells that migrated to the lower chamber were ﬁxed, stained, and counted using light microscopy. Migrated
cells to the lower chamber were quantiﬁed. Data expressed as means 6 SD (n = 4). *P , 0.05 compared with PBS. E) Scratch/
wound-healing assay for evaluating the inhibitory effects of MPS peptide on cell migration. Conﬂuent cultures of IPF-1 and IPF-2
cells were scratched and wound-healing repair was monitored microscopically at 12 and 24 h after the scratch with and without
addition of MPS peptide (100 mM). Left: phase contrast pictures. Right: numbers of cells migrated to the wound area were
quantiﬁed at 12 and 24 h postscratching (n = 4). *P , 0.05 vs. PBS. Data are representative of 3 independent experiments.
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decreased both phospho-AKT and a-SMA expression.
The combination treatment of MPS peptide and ninte-
danib on IPF fibroblasts showed that MPS peptide has
an inhibitory effect on nintedanib-enhanced a-SMA
expression. Given the effect ofMPSpeptide on reducing
phospho-AKT and a-SMA levels, we hypothesized that
MARCKS inhibition by MPS treatment may improve
nintedanib efficacy. To this end, the primary fibroblast
cells were treated with various doses of nintedanib
(62.5–2000 nM) and/or MPS peptide (6.25–200 mM) for
72 h. After either single or combination treatment, cell
viabilitywas decreased in IPF-1 (Fig. 7C) and IPF-2 (Fig.
7D) cells when treated with either nintedanib, the MPS
peptide, or a combination of both drugs, with the
greatest inhibition of viability observed in the combi-
nation group.
To evaluate the therapeutic interactions between
nintedanib and MPS peptide, we used the Chou and
Talalay CI method (36), and we demonstrated that the
addition of MPS substantially enhanced the viability
suppression of nintedanibwith a CI value;0.5 at ED50
(CI , 1), indicating the synergistic effect of drug
combination (Fig. 7E). Particularly, the values were
lower than 1 at ED50, ;1 at ED75, and above 1 at ED90
(unpublished results). Thus, the combination effect
was dose-dependently correlated with the com-
ponents, and therefore low-dose nintedanib in com-
bination with a low dose of MPS presents a synergistic
effect on cell proliferation. Simultaneously, data from
Trypan blue exclusion test indicated that cell survival
was significantly lower with the combination treat-
ment as compared with control, MPS, and nintedanib
(Fig. 7F). These data convincingly demonstrate that
MPS treatment enhances nintedanib efficacy in IPF
fibroblast cells and represents a viable and novel op-
tion for patients with IPF.
Figure 5. MPS peptide has an inhibitory effect on cell viability of a-SMA–expressing murine ﬁbroblasts. A) Representative
images of immunoﬂuorescence staining of phospho-MARCKS (red color) and a-SMA (green color) in lung tissues from
mice exposed to saline or bleomycin. DAPI (blue color): nucleus stains. B) Quantiﬁcation of phospho-MARCKS– and
a-SMA–positive staining cells (means 6 SD, n = 3). C ) Western blots analysis of phospho-MARCKS, phospho-AKT, and a-SMA
expression in lung ﬁbroblast cells isolated from saline- or bleomycin-treated mice after 48 h of treatment with 100 mM
control or MPS peptide. D) Effect of MPS peptide on cell viability of lung ﬁbroblasts isolated from saline- (mFb-Saline) or
bleomycin-treated (mFb-Bleomycin) mice using MTT assays (n = 4). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
*P , 0.05.
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DISCUSSION
IPF is a progressive fibrotic lung disease character-
ized by unregulated proliferation of fibroblasts and
excessive ECM deposition. In our current work, we
have identified MARCKS as a novel a-SMA regulator.
We observed increased levels of phospho-MARCKS in
clinical IPF lung tissues, in primary fibroblasts in vitro,
Figure 6. Suppressive effects of MPS peptide on pulmonary ﬁbrosis in vivo. A–C) C57BL/6 mice were intraperitoneally given
either PBS or MPS peptide at a dosage of 28 mg/kg every 2 d after mice intratracheally received 1 shot of saline or bleomycin (33
mg in 50 ml of saline, n = 5). Sequence of events (A) and body weight of mice (B) in bleomycin-induced pulmonary ﬁbrosis with
and without MPS treatment. C) Left: representative Masson trichrome–stained sections of mouse lung with various treatments.
Original magniﬁcation: 34 (top); 320 (bottom). Right: semiquantitative ﬁbrosis score from Masson trichrome–stained sections
of mouse lung. Fibrosis score is expressed as the percentage of positive staining area per high-powered ﬁeld. Analysis of 6–12
high-powered ﬁelds per lung was performed with ImageJ software. *P , 0.05. D, E) Bleomycin-exposed mice were
intraperitoneally given either nintedanib or MPS treatment at the dosage of 28 mg/kg every 2 d. D) Representative Masson
trichrome and IHC staining of phospho-MARCKS (Ser159/163) and phospho-AKT (Ser473) (n = 6). E) Hydroxyproline level in
the left lung of mice as described above was determined by a hydroxyproline ELISA assay (means 6 SD). *P , 0.05.
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and in bleomycin animal models correlated with
a-SMA expression (Figs. 1 and 5). Additionally, atten-
uation of phospho-MARCKS through MPS peptide
reduced a-SMA simultaneously with phospho-AKT
in vitro and ex vivo (Figs. 3 and 5). Inhibition
of phospho-MARCKS also reduced myofibroblast mi-
gration ability and survival in vitro, attenuated fibrosis
in the animal model (Figs. 4 and 6), as well as
down-regulated COL1A1 expression on the transcrip-
tional level. Lastly, we examined the effects of MPS
Figure 7. MPS peptide acts synergistically with nintedanib in IPF. A) Nintedanib treatment induces a-SMA protein
expression in primary IPF ﬁbroblasts. Cells were incubated with various doses of nintedanib as indicated. After 48 h,
cells were collected and subjected to Western blot analysis. B) Western blot analysis of a-SMA, phospho-MARCKS, and
phospho-AKT in primary IPF ﬁbroblasts with nintedanib (1000 nM) and/or MPS (100 mM) for 48 h. C–E ) Combinatorial
effect of MPS peptide with nintedanib on ﬁbroblasts isolated from 2 patients with IPF. C, D) Cells were treated with
various doses of nintedanib (62.5–2000 nM) and/or MPS peptide (6.25–200 mM) for 72 h, respectively. After single
(blue/red line) or combined (green line) treatment, cell viability was determined by MTT assays. E ) The Chou and
Talalay CI method was utilized to evaluate the therapeutic interactions between nintedanib and MPS peptide using the
Calcusyn software. Gray line, additive effect of the combination of MPS peptide and the drug is represented at CI = 1. F )
Cells were individually treated with 1 mM nintedanib, 100 mM MPS peptide, or combinations of 1 mM nintedanib and 100
mM MPS peptide. After 48 h, cell viability was determined by the Trypan blue exclusion assay (n = 3). GAPDH,
glyceraldehyde 3-phosphate dehydrogenase. *P , 0.05.
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peptide treatment in conjunction with nintedanib
treatment and observed marked reduction in a-SMA
correlated with reduction in phospho-MARCKS and
phospho-AKT (Fig. 7). Taken together, these findings
suggest a novel role ofMARCKS in IPF fibrogenesis and
offers a potential marker and promising therapeutic
target.
The histopathologic lesions in IPF are dominated by the
presence of increased ECM proteins (type I collagen–rich)
and accumulation of fibroblasts,which are the key effector
cells in fibrosis development (18, 40). Unlike quiescent or
resting fibroblasts, the majority of lung fibroblasts from
patients with IPF display an abnormally “activated”
phenotype, namely pathologic alterations in proliferation,
migration, anddifferentiation intomyofibroblasts (41–43).
The activated fibroblasts persist and proliferate, continu-
ing to produce collagen, which disrupts the normal lung
architecture. In light of the importance of activated fibro-
blasts in IPFprogression, the signalingmolecules regulating
fibroblast proliferation, migration, and differentiation are
coming into our focus. Herein, we identified phospho-
MARCKS as a candidate target for regulating fibroblast
activation. Our data showed a dramatic increase in
phospho-MARCKS levels in both IPF lung tissue sections
and primary fibroblast cells, indicating the clinical implica-
tionsof increasedphospho-MARCKS(MARCKSactivation)
in pulmonary fibrosis.
Indeed, lung fibroblasts derived from patients with
IPF displayed up-regulation of phospho-MARCKS and
MARCKS expression, which are highly associatedwith
expression of a-SMA, a myofibroblast marker. Down-
regulation of phospho-MARCKS led to the suppression
of fibroblast cell proliferation, migration, and/or
myofibroblast differentiation (a-SMA expression). Be-
cause phospho-MARCKS has been demonstrated to
play a role in lung cancer cell proliferation, invasion,
and migration (27, 28), it is logical that phospho-
MARCKS, and manipulation thereof, would have
similar effects on fibroblasts. Although MARCKS has
been extensively studied in many lung diseases, the
functional role of MARCKS has not been explored in
IPF and lung fibroblasts. To the best of our knowledge,
this is the first study on the efficacy of MPS as an anti-
fibrotic agent in IPF, and our results present MARCKS
as a druggable target in this disease.
Targeting both increased fibroblast proliferation and
myofibroblast differentiation has been considered as a
therapeutic strategy in IPF management; however, the
detailed mechanism of fibrosis remains unclear, and
effective treatment options remain limited (1–3, 5, 12,
13, 44). Although a few signaling proteins influencing
fibroblast activation and/or myofibroblast differentia-
tion, such as PDGFR, FGFR, VEGFR, TGF-b, and PI3K,
have been identified (9, 10, 21, 22, 45), the mechanisms
behind fibrotic disorders are still incomplete. Currently,
2 FDA-approved drugs that target the above pathways
for IPF are pirfenidone and nintedanib (30, 44). Al-
though effective at slowing progression, these drugs are
unable to completely stop or reverse progression. Ad-
ditionally, the exact mechanism of action for pirfeni-
done is unknown, and these drugs also come with a
plethora of detrimental side effects that necessitate
stopping treatment in the affected patients (4, 7, 12, 13,
46).Additionally,wehave observed that the PI3K/AKT
pathway is still active after nintedanib treatment in
vitro, suggesting that the drug is ineffective at inhibiting
PI3K/AKT activity. Despite having a defined mode of
action, the array of side effects and insufficient blocking
of AKT activity makes nintedanib an inadequate ther-
apeutic for IPF.
A previous study by Rangarajan et al. (39) suggested
that nintedanib treatment up-regulates a-SMA expres-
sion in fibroblasts. In agreement with this finding, we
also observed an increase of a-SMA expression in lung
fibroblasts of the patient with IPF after treatment with
nintedanib. Although nintedanib has shown effective-
ness in reducing fibroblast cell proliferation and mi-
gratory ability (7), it is not able to reduce phospho-AKT
and increases a-SMA on a transcriptional level. This
suggests that although nintedanib may be effective at
slowing fibroblast cell proliferation and motility, there
are alternative pathways that are still active, leading to
continuedprogression, perhaps offering an explanation
as to why nintedanib alone does not stop IPF progres-
sion. One such active pathway is the TGF-b/AKT/
a-SMA axis. We demonstrate that this axis is activated
in response to TGF-b stimulation in lung fibroblasts,
leading to an up-regulated level of a-SMA and phospho-
AKT.TheMPSpeptide can target this activation, resulting
in decreased a-SMA and reduced phospho-AKT activity
(Supplemental Fig. S2C). These findings indicate that
targeting the TGF-b pathway through attenuating PI3K/
AKT activity via PIP2 sequestration is an effective ap-
proach to addressing TGF-b-mediated myofibroblast dif-
ferentiation and activity.
In conjunction with associated adverse side effects,
there is a clear need to improve drug efficacy. In order to
tackle this problem, we implemented the novel use of
nintedanib in combination treatment in IPF fibroblasts.
Combination therapy itself is not a novel concept as it
has been effectively employed in the treatment of var-
ious cancer types. However, the use of combination
therapy is limited in IPF, and many combined treat-
ments do not offer significant improvements to IPF
progression and survival (46–49). In our study, we have
shown that the combination of nintedanib with MPS
peptide has shown a synergistic effect on attenuating
myofibroblast survival, proliferation, and migration,
especially at lower concentrations. This is potentially
due to the combinatorial effect of targeting VEGFR,
FGFR, andPDGFR in complimentwith targeting TGF-b
activity. Although nintedanib has been demonstrated
to target the downstream activities of VEGFR, FGFR,
and PDGFR (7), the TGF-b pathway is not sufficiently
targeted by this inhibitor. The addition of MPS peptide
in conjunction with nintedanib treatment allows for
more comprehensive attenuation of TGF-b and
AKT activity in lung fibroblasts (Figs. 5C and 7B and
Supplemental Fig. S2C). This presents itself as a prom-
ising approach to the treatment of IPF as lower dosages
of therapeutics could be achieved, thus potentially
mitigating side effects while improving IPF outcomes.
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There is mounting evidence pointing to the im-
portance of the PI3K/AKT pathway in fibrosis pro-
gression through promoting myofibroblast survival,
migration, and proliferation (20–23, 45, 50, 51). Given
that MARCKS plays a critical role in the regulation of
PI3K and subsequent AKT activity through modu-
lating PIP2 pools (27–29), we hypothesized a correla-
tion between the PI3K pathway and phospho-
MARCKS abundance in the context of IPF fibroblast
activation. MARCKS interacts with PIP2 at the cell
membrane through electrostatic interactions at the
PSD (52). In an unphosphorylated state, MARCKS
sequesters PIP2 pools via the PSD; however, after
PSD phosphorylation, MARCKS disassociates from
the membrane and exposes PIP2 to PI3K. Previously,
we have demonstrated the interaction between PI3K and
MARCKS in a panel of lung cancer cells (28). Targeting
MARCKS is an appealing approach as PIP2 to PIP3
synthesis is a universal step in PI3K signaling. In both
bleomycin animal models and in vitro assays, we ob-
served increased phospho-MARCKS levels in IPF fibro-
blasts or in fibroblasts isolated from bleomycin-treated
mice. Treatment with the MPS peptide targeting the
MARCKS PSD (28) in various IPF fibroblasts confirmed
that this peptide had an inhibitory effect on MARCKS
phosphorylation, AKT activity, cell proliferation, col-
ony formation, invasiveness, and motility, which is
consistentwith our previous findings in cancers (28, 30).
Additionally, we found that attenuation of phospho-
MARCKS significantly reduces the expression of myo-
fibroblast marker a-SMA and fibrotic marker collagen.
Importantly, the in vivo results are consistent with the
above in vitro findings and support the notion that the
25-mer peptide targeting the MARCKS PSD sequence,
MPS, has therapeutic applications as a novel antifibrotic
agent.
Targeting MARCKS and its signaling axis through
the use ofMPSpeptide to abrogatemyofibroblasts, both
in vitro and in vivo, serves as a proof of concept for
suppressing IPF progression. Currently, a large number
of potential antifibrotic compounds are given as pre-
ventive treatment in preclinical studies; as a result, the
translation of these findings into clinical practice has
not been very successful (46, 53, 54). To better reflect the
management of human IPF and to reveal beneficial
compounds, we evaluated the antifibrotic properties of
the MPS peptide in the phase of established fibrosis in
mice. We believe the therapeutic potential of this novel
peptide in bleomycin-induced pulmonary fibrosis was
demonstrated for the first time and will contribute
to development of treatments that destroy activated
fibroblasts without adversely affecting quiescent
fibroblasts.
In summary, our results suggest phospho-MARCKS as
a promising therapeutic target in IPF. As TGF-b signaling
is not completely blocked by multikinase inhibitors such
as nintedanib, the PI3K/AKT pathway is still active in
myofibroblasts in IPF. Attenuation of MARCKS, an up-
stream regulator of PI3K, via MPS peptide was shown to
reduce fibrotic markers and fibrosis both in vitro and in
vivo. Furthermore,we have shown combination treatment
of MPS peptide and nintedanib to be an effective and
promising approach in addressing the current lack of
effective treatments. Taken together, we have shown
MARCKS to be an important player and target, further
elucidated the mechanisms involved in fibrosis, and in-
troducedanovel andpromisingapproach in the treatment
of IPF.
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